53. シェーグレン症候群 Disease details / Clinical trials / Drug dev / DR info

0.005% lacripep
   TearSolutions, Inc.
      2017   Phase 1/Phase 2   NCT03226444   United States
0.01% lacripep
   TearSolutions, Inc.
      2017   Phase 1/Phase 2   NCT03226444   United States
0.02% FM, SH, 0.05% CSA
   Jinyang Li
      2013   -   NCT02147509   China
0.02% FM, SH, AS
   Jinyang Li
      2013   -   NCT02147509   China
0.02% FM, SH, tbcl
   Jinyang Li
      2013   -   NCT02147509   China
0.9% sodium chloride
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom
   The First Affiliated Hospital of Xiamen University
      2025   -   ChiCTR2500099859   China
13-valent pneumococcal conjugate vaccine
   Region Skane
      2016   Phase 4   NCT03762824   -
1643368-58-4
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
23-valent pneumococcal polysaccharide vaccine
   Region Skane
      2016   Phase 4   NCT03762824   -
552-02
   Parion Sciences
      2009   Phase 2   NCT00852839   United States
68GA-P16-093
   Peking Union Medical College Hospital
      2023   Phase 1/Phase 2   NCT06049368   -
Abatacept
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb K.K.
      2017   Phase 3   JPRN-jRCT2080223466   Argentina, Brazil, Canada;Asia except Japan;Czech Republic, Germany, France;Europe;Italy, Mexico, Puerto Rico;Japan;Japan, Korea, US, Australia;North America;Oceania;South America;Sweden
   The Cleveland Clinic
      2013   Phase 2   NCT02027298   United States
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
Abatacept SC
   University Medical Center Groningen
      2014   Phase 3   NCT02067910   Netherlands
ABBV-323
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-003131-31-NL   Netherlands
Acetylcysteine
   The Fourth Affiliated Hospital of Nanjing Medical University
      2023   Phase 4   ChiCTR2300071950   China
Acupuncture combined with oral hydroxychloroquine sulfate tablets
   Senyue Zhang
      2023   -   NCT06432101   China
Acupuncture GB20 or GB20 plus BL2
   Taipei Veterans General Hospital, Taiwan
      2025   -   NCT06771427   Taiwan
Acycloguanosine
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Alginate
   Teikyo University
      2009   -   JPRN-UMIN000029307   Japan
Allogeneic stem cell transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States
AMG 557/MEDI5872
   MedImmune LLC
      2015   Phase 2   NCT02334306   France;Sweden;United Kingdom;United States
   MedImmune, LLC
      2015   Phase 2   EUCTR2014-003896-41-GB   France;Sweden;United Kingdom;United States
Anifrolumab
   University Medical Center Groningen
      2022   Phase 2   NCT05383677   Netherlands
   University Medical Centre Groningen
      2022   Phase 2   EUCTR2022-000609-28-NL   Netherlands
ANTI-CD19 CAR T cell therapy
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06828042   -
ANTI-CD19 CAR-NK cells
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2025   -   NCT06614270   China
ANTI-CD19 CAR-T cells
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06821659   -
ANTI-CD19-CAR-T cells
   First Affiliated Hospital of Wenzhou Medical University
      2024   Early Phase 1   NCT06420154   China
ANTI-CD19-CD3E-CAR-T cells
   Shanghai Changzheng Hospital
      2024   -   NCT06373081   China
ANTI-CD28DAB
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
Arava
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
ARGX-113
   argenx BV
      2023   Phase 2   EUCTR2021-005911-30-BE   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
      2022   Phase 2   EUCTR2021-005911-30-NL   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
Artificial saliva
   Pontificia Universidad Catolica de Chile
      2006   Phase 4   NCT00438048   Chile
Ascs
   Rigshospitalet, Denmark
      2020   Phase 2   NCT04615455   Denmark
ASP5502
   Astellas Pharma Global Development, Inc.
      2024   Phase 1   NCT06544642   United States
Assigned interventions CD19/bcma CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05085431   China
Autologous serum
   Hospital Nacional Profesor Alejandro Posadas
      2017   Phase 4   NCT03608761   Argentina
   Instituto de Oftalmología Fundación Conde de Valenciana
      2024   Phase 3   NCT06931041   Mexico
   Pontificia Universidad Catolica de Chile
      2018   Phase 3   NCT03436576   Chile
Autologous serum tears combined with 0.05% cyclosporin EYE drop
   Chengdu University of Traditional Chinese Medicine
      2022   -   NCT06013436   China
Autologous stem cell transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States
AúN NO establecido
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004387-54-ES   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
Baminercept
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 2   NCT01552681   United States
Baricitinib
   Peking Union Medical College Hospital
      2022   Phase 2   NCT05016297   China
Baricitinib 2 MG
   Peking Union Medical College Hospital
      2020   Phase 1/Phase 2   NCT04916756   China
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
Bcma/CD19 CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06428188   China
Belimumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2009-015978-35-FR   France
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT01160666   France
   GlaxoSmithKline
      2016   Phase 2   NCT02631538   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06410833   China
Biopsy OF THE labial salivary gland
   University Hospital, Bordeaux
      2020   -   NCT03841318   France
Biospecimen collection
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Blood sample
   University Hospital, Bordeaux
      2020   -   NCT03841318   France
   University Hospital, Limoges
      2010   -   NCT01081184   France
BMS-188667
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
BMS-931699
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb
      2016   Phase 2   NCT02843659   Australia;Chile;Colombia;France;Hungary;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb
      2016   Phase 2   NCT02843659   Australia;Chile;Colombia;France;Hungary;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
BMS-986325
   Bristol-Myers Squibb
      2021   Phase 1   NCT04684654   Germany;United States
BMS986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
Branebrutinib
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
BRL-301
   Bioray Laboratories
      2023   -   NCT05859997   China
BTK inhibitor
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BUPI5
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark
Bupivacaine hydrochloride
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark
Bupizenge
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark
Calcium carbonate D
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China
CAR-NK cell
   Bangdong Gong
      2025   Phase 1/Phase 2   NCT06967038   China
Carbomer
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom
Carbomer 974P
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Carbomer GEL/jelly
   Chang Gung Memorial Hospital
      2023   -   NCT06406933   Taiwan
Carboxy methyl cellulose
   Cairo University
      2021   Phase 3   NCT04252209   Egypt
Cathepsin S
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
Cathepsin S inhibitor
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
CD19 targeted CAR-T cells
   Chongqing Precision Biotech Co., Ltd
      2023   Phase 1   NCT06056921   China
CD19- bcma CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06350110   China
CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2025   Phase 1/Phase 2   NCT06947460   China
CDZ173
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2014-004616-12-PL   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-HU   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-DE   Germany;Hungary;Poland
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02775916   Germany;Hungary
Cenegermin
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
Cepharanthin
   Department of Oral Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School
      2015   -   JPRN-UMIN000019242   Japan
   Department of Oral Medicine, Institute of Health Biosciences, The University of Tokushima Graduate Faculty of Dentistry
      2011   -   JPRN-UMIN000005878   Japan
Cepharanthine
   Yamanoi Tomoko
      2011   Phase 2-3   JPRN-jRCTs061180072   -
Cevimeline
   Department of Dentistry and Oral Surgery, Tochigi National Hospital
      2008   Phase 1   JPRN-UMIN000000997   Japan
   The Affiliated Huai'an Hospital of Xuzhou Medical University
      2020   Phase 0   ChiCTR2000033420   China
CFZ533
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-001942-20-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-001942-20-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Türkiye;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-SI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2013-004808-19-DE   Germany;Hungary;Switzerland;United Kingdom;United States
      2014   Phase 2   EUCTR2013-004808-19-HU   Germany;Hungary;Switzerland;United Kingdom
      2014   Phase 2   EUCTR2013-004808-19-GB   Germany;Hungary;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04541589   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   NCT03905525   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
CFZ533 active - cohort 1
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
CFZ533 active - cohort 2
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
CFZ533 active - cohort 3
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
CFZ533 active -cohort 3
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
Chinese herbal TEA tbdesjs
   Taipei Veterans General Hospital, Taiwan
      2025   -   NCT06771427   Taiwan
Ciclosporin
   Charité Berlin, Department of rheumatology
      -   -   EUCTR2009-013976-38-DE   Germany
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
Citric acid
   Juntendo university Urayasu Hospital
      2018   -   JPRN-UMIN000053206   Japan
Citric acid based mouthwash
   Grupo de Investigação em Bioquímica e Biologia Oral
      2013   Phase 4   NCT03578900   -
Comirnaty concentrate FOR dispersion FOR injection
   University Medical Center Groningen
      2021   Phase 4   EUCTR2021-001414-10-NL   Netherlands
Cryostor CS10
   Rigshospitalet, Denmark
      2020   Phase 2   NCT04615455   Denmark
Cyclosporin A
   National Eye Institute (NEI)
      1997   Phase 2   NCT00001731   United States
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China
Cyclosporine
   Peking University First Hospital
      2022   Phase 4   ChiCTR2500099615   China
   Peking University Third Hospital
      2021   -   NCT05605314   China
Cyclosporine 0.09% ophthalmic solution
   Center for Ophthalmic and Vision Research, LLC
      2021   Phase 4   NCT04835623   United States
Cyclosporins
   Pavly Moawd
      2018   Phase 3   NCT03865888   Egypt
Dazodalibep
   Amgen
      2025   Phase 3   NCT06747949   Germany;United States
      2024   Phase 3   NCT06245408   Argentina;Australia;Belgium;Brazil;Canada;Chile;Croatia;Denmark;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Peru;Poland;Portugal;Puerto Rico;Serbia;Slovenia;Spain;Taiwan;United Kingdom;United States
      2024   Phase 3   NCT06104124   Argentina;Australia;Belgium;Brazil;Canada;Chile;Croatia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Peru;Poland;Portugal;Puerto Rico;Serbia;Slovenia;Spain;Taiwan;United Kingdom;United States
   Shimoyama Michio
      2024   Phase 3   JPRN-jRCT2061230107   Europe;Japan;North, Central and South America;the Asia-Pacific
Dehydroepiandrosterone
   Helsinki University
      2003   Phase 4   NCT00543166   Finland
   National Institute of Dental and Craniofacial Research (NIDCR)
      1997   Phase 2   NCT00001598   United States
   UMC Utrecht
      2000   Phase 2   NCT00391924   Netherlands
Deucravacitinib
   Bristol-Myers Squibb
      2023   Phase 3   NCT05946941   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Portugal;Puerto Rico;Romania;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
Dexamethasone parotid irrigation
   National Institute of Dental and Craniofacial Research (NIDCR)
      2011   Phase 2   NCT01316770   United States
Diquafosol
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
Dornase alfa
   UConn Health
      2011   Phase 1   NCT01357447   United States
DR-0201
   Dren Bio
      2025   Phase 1   NCT06647069   Australia;Bosnia and Herzegovina;Bulgaria;New Zealand;Poland;Serbia;South Africa
Efalizumab
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Efgartigimod
   argenx
      2023   Phase 2   NCT06203457   Belgium;Hungary;Poland
      2023   Phase 2   NCT05817669   Belgium;Hungary;Netherlands;Poland
Efgartigimod alfa
   argenx BV
      2023   Phase 2   EUCTR2021-005911-30-BE   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
      2022   Phase 2   EUCTR2021-005911-30-NL   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
Escherichia coli
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
Estetrol
   Erasmus MC
      2008   -   EUCTR2007-003537-16-NL   Netherlands
Etanercept
   National Institute of Dental and Craniofacial Research (NIDCR)
      1999   Phase 2   NCT00001954   United States
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Evadry
   University Tunis El Manar
      2024   -   NCT06313905   -
Filgotinib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
FMP-30
   University of Miami
      2019   Phase 1   NCT03926286   United States
G1567970
   Galapagos NV
      2021   Phase 2   EUCTR2020-003298-22-HU   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-GR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-FR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-ES   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-DE   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;United Kingdom
GLPG3970
   Galapagos NV
      2021   Phase 2   NCT04700280   France;Germany;Greece;Hungary;Poland;Spain;Ukraine
      2021   Phase 2   EUCTR2020-003298-22-HU   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-GR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-FR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-ES   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-DE   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;United Kingdom
Glycyrrhiza
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037057   China
GS-4059
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
GS-6034
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
GS-9876
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
GSK2618960
   GlaxoSmithKline Research & Development Limited
      2017   Phase 2   EUCTR2016-004258-14-GB   United Kingdom
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
HGS1006, lymphostat-B
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2009-015978-35-FR   France
HRIL-2 active
   Peking University People's Hospital
      2015   Phase 2   NCT02464319   China
Hydrocortisone
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands
Hydrocortisone sodium phosphate
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
Hydroxychloroquine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00632866   France
   Aviation General Hospital
      2022   Phase 1   ChiCTR2300078648   China
   Ege University
      2005   -   NCT00873496   Turkey
   Kanazawa University Graduate School of Medical Science
      2010   -   JPRN-UMIN000004477   Japan
   Peking Union Medical College Hospital
      2022   Phase 2   NCT05016297   China
   Peking University People's Hospital
      2025   Phase 2   NCT06862284   China
   Seoul National University Hospital
      2011   Phase 3   NCT01601028   Korea, Republic of
   Shanghai Tongji Hospital
      2019   Phase 4   ChiCTR1900022696   China
   Tongji Hospital of Tongji University
      2018   -   ChiCTR1800014623   China
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands
   Yueyang Hospital of Integrative Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
      2014   Phase 1 study   ChiCTR-IPR-14005441   -
Hydroxychloroquine 400MG/D
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   France
Hydroxychloroquine sulfate
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   Beijing Hospital
      2023   -   ChiCTR2300069222   China
   Ningbo Medical Center Lihuili Hospital
      2022   Phase 4   ChiCTR2200057578   China
   Qingwen Tao
      2024   Phase 2   NCT06519617   China
Hydroxychloroquine sulfate tablets
   China-Japan Friendship Hospital
      2022   -   ChiCTR2200061608   China
      2020   -   ChiCTR2000037989   China
   Guang’anmen Hospital,China Academy of Chinese Medical Sciences
      2024   Phase 1   ChiCTR2400079948   China
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04981145   China
HZN-1116
   Amgen
      2024   Phase 2   NCT06312020   Argentina;Austria;Bulgaria;Chile;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Poland;Portugal;Spain;Switzerland;Taiwan;United Kingdom;United States
Ianalumab
   Hirano Takamitsu
      2022   Phase 3   JPRN-jRCT2041220098   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Russia;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
   Maruyama Hideki
      2023   Phase 3   JPRN-jRCT2041240054   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Russia;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-IT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2021-005687-22-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-IS   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-GR   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005661-14-PT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-PL   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-LT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-FR   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-DE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-BE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-AT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 2   EUCTR2020-005055-20-FR   France
      2017   Phase 2   EUCTR2016-003292-22-PT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-PL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-NL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-GB   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-DE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-BE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-AT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2023   Phase 3   NCT05985915   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 2   NCT05124925   France
IBI355
   Innovent Biologics (Suzhou) Co. Ltd.
      2024   Phase 1   NCT06484855   China
Iguratimod
   Chongqing Hospital of Traditional Chinese Medcine
      2019   -   ChiCTR1900024642   China
   Huzhou Third People's Hospital
      2023   Phase 1   ChiCTR2300072206   China
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2021   Phase 2   NCT04830644   China
   Peking Union Medical College Hospital
      2017   Phase 1/Phase 2   NCT03023592   China
   Shanghai Tongji Hospital
      2019   Phase 4   ChiCTR1900022696   China
   Tianjin Medical University General Hospital
      2019   -   ChiCTR1900021345   China
Iguratimod tablets
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04981145   China
Ikervis
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
IL-2
   the Second Hospital of Shanxi Medical University
      2017   -   ChiCTR-INR-17011220   China
IMVT-1402
   Immunovant Sciences GmbH
      2025   Phase 2   NCT06979531   -
Inactivated and fragmented influenza vaccine (A / michigan / 45/2015 (H1n1) PDM09-like virus, A / singapore / infimh-16-0019 / 2016 (H3n2) -like virus
   University of Sao Paulo General Hospital
      2018   Phase 4   NCT03540823   Brazil
Insulin lispro
   Instituto de Oftalmología Fundación Conde de Valenciana
      2024   Phase 3   NCT06931041   Mexico
Iscalimab
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-001942-20-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-001942-20-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Türkiye;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-SI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma. K.K.
      2019   Phase 2   JPRN-jRCT2080224883   Asia except Japan;Europe;Japan;North America;Oceania;South America
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04541589   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Sweden;Turkey;United Kingdom;United States
   Yamada Hiroyuki
      2019   Phase 2   JPRN-jRCT2071200072   Australia;Hungary;Japan
JNJ-80202135
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-FR   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
KCT-0809 ophthalmic solution
   Kissei Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02503189   Japan
      2016   Phase 3   NCT02503163   Japan
      2015   Phase 3   NCT02503176   Japan
Korean RED ginseng
   Hanyang University
      2019   -   NCT03983408   Korea, Republic of
Lacryvisc
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Lanraplenib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States
Leflunomide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands
Leflunomide 20MG/D
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   France
Leflunomide mylan
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands
Leniolisib
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2014-004616-12-PL   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-HU   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-DE   Germany;Hungary;Poland
Levocarnitine
   Vanderbilt University Medical Center
      2021   Phase 2   NCT03953703   United States
Levofloxacin
   The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
      2020   Phase 1   ChiCTR2000034924   China
Licorice
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037057   China
Limphostat-B
   University of Udine
      2009   Phase 2   NCT01008982   Italy
Liposic
   LanZhou University
      2018   -   NCT03434106   China
   Tung Wah Hospital
      2017   -   NCT03060005   China
LO2A EYE drops
   Ocuwize LTD
      2018   Phase 4   NCT03319420   Israel
LOU064
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004387-54-ES   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 2   EUCTR2018-004387-54-BG   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-HU   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-GB   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DK   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-BE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
LOW-dose interleukin-2
   Peking University People's Hospital
      2022   Phase 1/Phase 2   NCT05605665   China
LY3090106
   Eli Lilly and Company
      2015   Phase 1   NCT02614716   Bulgaria;Georgia;Romania;United States
   Matthew C. Baker
      2021   Phase 2/Phase 3   NCT04563195   United States
LY3361237
   Stanford University
      2025   Phase 2   NCT05781451   -
M281
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-FR   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
Maxidex
   Alcon Research
      2008   Phase 4   NCT00631358   Canada
MEDI4920
   Viela Bio, Inc.
      2020   Phase 2   EUCTR2019-002713-19-PL   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-HU   Argentina;China;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-GB   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Turkey;United Kingdom;United States
Methotrexate
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
MHV370
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2020-004937-19-ES   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-004937-19-HU   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
      2021   Phase 2   EUCTR2020-004937-19-DE   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04988087   China;Germany;Hungary;Poland;Spain;Switzerland;Taiwan;United Kingdom
Micofenolato mofetile
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Mighteaflow
   Augusta University
      2011   Phase 1/Phase 2   NCT01647737   United States
Mirabegron
   China Medical University Hospital
      2021   Phase 4   NCT04909255   Taiwan
Mizoribine
   Graduate School of Medicine, Chiba University
      2013   Phase 2   JPRN-UMIN000004237   Japan
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Mrna COVD19 vaccine
   Mayo Clinic
      2021   Early Phase 1   NCT04839315   United States
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Mycophenolate mofetil
   Kaohsiung Medical University
      2016   Phase 2   NCT02691949   -
Mycophenolate mofetil 2000MG/D
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   France
Mycophenolate mofetil teva
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Mycophenolate sodium
   University Hospital Muenster
      2005   Phase 1   NCT00542763   Germany
N-acetylcysteine syrup
   University of Sao Paulo General Hospital
      2021   -   NCT04793646   Brazil
Natural herbs OF coconut, aloe vera, and pepperint
   Cairo University
      2021   Phase 3   NCT04252209   Egypt
Nerve growth factor
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
NGX267
   TorreyPines Therapeutics
      2008   Phase 2   NCT00637793   United States
Nipocalimab
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen Research & Development, LLC
      2024   Phase 3   NCT06741969   Argentina;Brazil;China;Japan;Korea, Republic of;Mexico;Taiwan;United Kingdom;United States
      2021   Phase 2   NCT04968912   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-FR   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Nishikawa Kazuko
      2022   Phase 2   JPRN-jRCT2031210484   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States Of America
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
NO treatment
   Alcon Research
      2008   Phase 4   NCT00631358   Canada
Olive OIL
   University of Sao Paulo General Hospital
      2010   Phase 4   NCT01850979   Brazil
Omalizumab
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2014   Phase 1   NCT01716312   United States
Omega 3 fatty acid
   Hawler Medical University
      2021   Phase 2/Phase 3   NCT05005806   Iraq
Ophthalmic emulsion
   Allergan
      2001   Phase 3   NCT00025818   United States
Orencia
   Arthritis & Rheumatism Associates, P.C.
      2016   Phase 2   NCT03411850   United States
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
      2010   Phase 2   EUCTR2009-015558-40-NL   Netherlands
Orencia 125 MG solution FOR injection IN PRE-filled syringe
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
OSE-127
   Institut de Recherches Internationales Servier
      2021   Phase 2   EUCTR2020-001526-59-DE   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-HU   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-GB   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
Oxervate
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
Oxybutynin, tolterodine, solifenacin
   China Medical University Hospital
      2021   Phase 4   NCT04909255   Taiwan
P-552
   Parion Sciences
      2010   Phase 1/Phase 2   NCT01369589   United States
Parsaclisib
   Incyte Corporation
      2019   Phase 2   NCT03627065   United States
Pilocarpine
   Oita University Faculty of Medicine
      2013   -   JPRN-UMIN000010796   Japan
   Pontificia Universidad Catolica de Chile
      2006   Phase 4   NCT00438048   Chile
   Teikyo University
      2009   -   JPRN-UMIN000029307   Japan
Pilocarpine hydrochloride
   Department of Pediatrics, Graduate School of Medicine, Chiba Univerity
      2008   -   JPRN-UMIN000001460   Japan
   Federal University of São Paulo
      2005   Phase 3   NCT04470479   Brazil
Plaquenil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-005218-38-FR   France
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands
PRE-filled syringe
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2021-005687-22-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-IS   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-GR   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005661-14-PT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-PL   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-LT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-FR   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-DE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-BE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-AT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 2   EUCTR2020-001942-20-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Türkiye;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
Prednisone
   Chongqing Hospital of Traditional Chinese Medcine
      2019   -   ChiCTR1900024642   China
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China
   Yueyang Hospital of Integrated Medicine affiliated to Shanghai University of Tradition Chinese Medicine
      2017   -   ChiCTR-INR-16009629   China
Privigen 100 MG/ML, solution pour perfusion
   Hôpitaux Universitaires de Strasbourg
      2019   Phase 3   EUCTR2017-001371-24-FR   France
Privigen® 100MG/ML AT THE dose OF 2G/KG OF body weight
   University Hospital, Strasbourg, France
      2019   Phase 3   NCT03700138   France
Probiotic product - CAP
   Cairo University
      2018   Phase 1/Phase 2   NCT03840538   Egypt
PRP injection
   Universidad Nacional de Colombia
      2014   Phase 3   NCT02257957   -
R-2487
   Rise Therapeutics LLC
      2025   Phase 1   NCT06297213   -
Rapamycin
   Peking University People's Hospital
      2022   Phase 1/Phase 2   NCT05605665   China
Raptiva
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 2   NCT00344448   United States
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Ravagalimab
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-003131-31-NL   Netherlands
RC18 160 MG
   RemeGen Co., Ltd.
      2019   Phase 2   NCT04078386   China
RC18 240 MG
   RemeGen Co., Ltd.
      2019   Phase 2   NCT04078386   China
RD06-04 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06549296   China
RD06-04 or RD06-05 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06548607   China
Rebamipide
   Hospital Nacional Profesor Alejandro Posadas
      2017   Phase 4   NCT03608761   Argentina
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
   Otsuka Pharmaceutical Co., Ltd.
      2005   Phase 2   NCT00233363   Japan
      2005   Phase 2   JPRN-jRCT2080220036   Japan
   Tochigi medical center
      2013   Phase 2   JPRN-UMIN000010710   Japan
   University of Alexandria
      2020   -   NCT01759108   Egypt
Refresh endura
   Federal University of São Paulo
      2013   Phase 4   NCT02004067   Brazil
Remibrutinib
   Novartis Pharma AG
      2021   Phase 2   EUCTR2018-004387-54-BG   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-GB   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DK   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-BE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04035668   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Spain;Switzerland;Taiwan;United Kingdom;United States
Restasis
   Federal University of São Paulo
      2013   Phase 4   NCT02004067   Brazil
Rice/turkey free diet (R/TFD) group
   University of Palermo
      2023   -   NCT05644795   Italy
Rituximab
   GlaxoSmithKline
      2016   Phase 2   NCT02631538   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   National Institute of Allergy and Infectious Diseases (NIAID)
      2004   Phase 1   NCT00101829   United States
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06410833   China
   University Medical Centre Groningen
      2006   Phase 1/Phase 2   NCT00363350   Netherlands
   University of Leeds
      2010   -   EUCTR2010-021430-64-GB   United Kingdom
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan
Rituximab, mabthera
   University of Copenhagen
      2007   Phase 2   NCT00426543   Denmark
RO545-9072/F03
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
RO5459072
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
   Hoffmann-La Roche
      2016   Phase 2   NCT02701985   France;Germany;Poland;Portugal;United Kingdom;United States
RSLV-132
   Resolve Therapeutics
      2024   Phase 2   NCT06440525   United States
      2017   Phase 2   NCT03247686   United Kingdom
   Resolve Therapeutics, LLC
      2016   Phase 2   EUCTR2016-001586-87-GB   United Kingdom
S95011
   Institut de Recherches Internationales Servier
      2021   Phase 2   EUCTR2020-001526-59-DE   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-HU   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-GB   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
S95011 concentrate FOR solution FOR infusion
   Institut de Recherches Internationales Servier
      2021   Phase 2   NCT04605978   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
SA001 high dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of
SA001 LOW dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of
SA001 MID dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of
Saline
   Affiliated Stomatological Hospital of Nanjing Medical University
      2021   Phase 4   ChiCTR2100052314   China
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
   The Fourth Affiliated Hospital of Nanjing Medical University
      2023   Phase 4   ChiCTR2300071950   China
   UConn Health
      2011   Phase 1   NCT01357447   United States
Sandimmun optoral
   Charité Berlin, Department of rheumatology
      -   -   EUCTR2009-013976-38-DE   Germany
Saphnelo
   University Medical Centre Groningen
      2022   Phase 2   EUCTR2022-000609-28-NL   Netherlands
SAR441344
   Sanofi
      2020   Phase 2   NCT04572841   Argentina;Belgium;Canada;Chile;France;Germany;Hungary;Korea, Republic of;Mexico;Spain;Taiwan;United States
   Sanofi-Aventis Recherche & Développement
      2020   Phase 2   EUCTR2020-000511-77-HU   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States
      2020   Phase 2   EUCTR2020-000511-77-DE   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States
      2020   Phase 2   EUCTR2020-000511-77-BE   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States
SHJ002
   Sunhawk Vision Biotech, Inc.
      2024   Phase 2   NCT06381986   Taiwan
Sialoendoscopy
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands
Sodium chloride
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Sodium hyaluronate
   Eye Institute of Xiamen University
      2016   Phase 4 study   ChiCTR-OIB-16007789   China
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Softacort
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
SS-1
   Chang Gung Memorial Hospital
      2014   Phase 2   NCT02110446   Taiwan
   China Medical University Hospital
      2014   Phase 2   NCT02855658   Taiwan
Standard care hyaluronic acid EYE drops
   Universidad Nacional de Colombia
      2014   Phase 3   NCT02257957   -
Standard OF care treatment
   Janssen Research & Development, LLC
      2024   Phase 3   NCT06741969   Argentina;Brazil;China;Japan;Korea, Republic of;Mexico;Taiwan;United Kingdom;United States
      2021   Phase 2   NCT04968912   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Nishikawa Kazuko
      2022   Phase 2   JPRN-jRCT2031210484   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States Of America
Sulfate D'hydroxychloroquine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-005218-38-FR   France
SVS20
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Systane ultra UD
   Ocuwize LTD
      2018   Phase 4   NCT03319420   Israel
T cell injection targeting CD19 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2024   Early Phase 1   NCT06417398   -
      2024   -   NCT06361745   China
Tacrolimus
   Eye Institute of Xiamen University
      2016   Phase 4 study   ChiCTR-OIB-16007789   China
   Pavly Moawd
      2018   Phase 3   NCT03865888   Egypt
   The Eye Hospital of Wenzhou Medical University
      2018   -   ChiCTR-IPR-17013772   China
   University of Sao Paulo General Hospital
      2010   Phase 4   NCT01850979   Brazil
TCM (GAN-LU-YIN)GLY
   Chung Shan Medical University
      2016   Phase 2   NCT04111341   Taiwan
Tears naturale forte
   LanZhou University
      2018   -   NCT03434106   China
   Tung Wah Hospital
      2017   -   NCT03060005   China
Telitacicept
   The First Affiliated Hospital of China University of Science and Technology
      2023   Phase 0   ChiCTR2300068254   China
   the First People's Hospital of qinzhou
      2024   -   ChiCTR2400079432   china
Telitacicept 160 MG
   RemeGen Co., Ltd.
      2023   Phase 3   NCT05673993   China
Telitacicept 80 MG
   RemeGen Co., Ltd.
      2023   Phase 3   NCT05673993   China
Tetracycline
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Thalidomide
   National Institute of Dental and Craniofacial Research (NIDCR)
      1997   Phase 2   NCT00001599   United States
Thymosin beta 4 EYE drops
   Michigan Cornea Consultants, PC
      2011   Phase 2   NCT01393132   United States
Tibulizumab
   Matthew C. Baker
      2021   Phase 2/Phase 3   NCT04563195   United States
Tirabrutinib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
Tivanisiran sodium ophthalmic solution
   Sylentis, S.A.
      2021   Phase 3   NCT04819269   Spain;United States
Tocilizumab
   University Hospital, Strasbourg, France
      2013   Phase 2/Phase 3   NCT01782235   France
Tofacitinib
   Beijing Hospital
      2023   -   ChiCTR2300069222   China
   National Institute of Dental and Craniofacial Research (NIDCR)
      2021   Phase 1/Phase 2   NCT04496960   United States
   Ningbo Medical Center Lihuili Hospital
      2022   Phase 4   ChiCTR2200057578   China
   Peking University People's Hospital
      2021   Phase 2   NCT05087589   China
Triamcinolone
   Affiliated Stomatological Hospital of Nanjing Medical University
      2021   Phase 4   ChiCTR2100052314   China
UCB5857
   UCB CELLTECH (UK BRANCH OF UCB PHARMA SA)
      2015   Phase 2   EUCTR2014-004523-51-IT   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   UCB Celltech
      2015   Phase 2   NCT02610543   France;Greece;Italy;Spain;Sweden;United Kingdom
   UCB Celltech, UK
      2017   Phase 2   EUCTR2014-004523-51-GR   France;Greece;Italy;Spain;Sweden;United Kingdom
      2016   Phase 2   EUCTR2014-004523-51-SE   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-004523-51-GB   France;Greece;Italy;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-004523-51-FR   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-004523-51-ES   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
Umbilical cord blood CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2025   Phase 1/Phase 2   NCT06947473   -
Upadacitinib
   Peking University People's Hospital
      2025   Phase 2   NCT06862284   China
Ustekinumab
   University of Rochester
      2020   Phase 1   NCT04093531   United States
Varenicline nasal spray
   University of Pennsylvania
      2023   Phase 4   NCT05700422   United States
VAY736
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-IT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2021-005687-22-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-IS   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-GR   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005661-14-PT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-PL   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-LT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-FR   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-DE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-BE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-AT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 2   EUCTR2020-005055-20-FR   France
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-000250-22-DE   Germany
   Novartis Pharmaceuticals
      2023   Phase 3   NCT05985915   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   NCT05350072   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   NCT05349214   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   NCT02962895   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2014   Phase 2   NCT02149420   France;Germany;Netherlands;United States
VAY736 antibody
   Novartis Farmacéutica, S.A.
      2017   Phase 2   EUCTR2016-003292-22-ES   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2017   Phase 2   EUCTR2016-003292-22-PT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-PL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-NL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-HU   Argentina;Austria;Belgium;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-GB   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-FR   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-DE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-BE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-AT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
VAY736 higher dose
   Novartis Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02495129   Netherlands
VAY736 lower dose
   Novartis Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02495129   Netherlands
Vehicle
   Lubris Bio Pty Ltd
      2024   Phase 1/Phase 2   NCT06520202   -
   Sunhawk Vision Biotech, Inc.
      2024   Phase 2   NCT06381986   Taiwan
Vehicle control
   Michigan Cornea Consultants, PC
      2011   Phase 2   NCT01393132   United States
Vehicle ophthalmic solution
   Sylentis, S.A.
      2021   Phase 3   NCT04819269   Spain;United States
VIB4920
   Amgen
      2019   Phase 2   NCT04129164   Argentina;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States
   VIELABIO Inc.
      2020   Phase 2   EUCTR2019-002713-19-IT   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States
   Viela Bio, Inc.
      2020   Phase 2   EUCTR2019-002713-19-PL   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-HU   Argentina;China;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-GB   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Turkey;United Kingdom;United States
VIB7734
   Amgen
      2018   Phase 1   NCT03817424   Poland;Spain;United States
Vitamin A
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
Vitamin D3
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Water
   Department of Dentistry and Oral Surgery, Tochigi National Hospital
      2008   Phase 1   JPRN-UMIN000000997   Japan
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2024   -   ChiCTR2400093768   China
Wheat/milk free diet (W/MFD) group
   University of Palermo
      2023   -   NCT05644795   Italy
Xeros
   Grupo de Investigação em Bioquímica e Biologia Oral
      2013   Phase 4   NCT03578900   -
Xylitol
   Augusta University
      2011   Phase 1/Phase 2   NCT01647737   United States
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil
YI QI yang YIN decoction
   Qingwen Tao
      2024   Phase 2   NCT06519617   China
YTS109 cell
   China Immunotech (Beijing) Biotechnology Co., Ltd.
      2025   Phase 1   NCT06978647   -